These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37400384)

  • 1. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
    Wu X; Li P; Mi YQ
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.
    Yi S; Ren G; Zhu Y; Cong Q
    Virol J; 2024 Jan; 21(1):22. PubMed ID: 38243304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.
    Jiang C; Liu J; Li R; Chen K; Peng W; Fu L; Peng S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):698-706. PubMed ID: 37539572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
    Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
    Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis.
    Zheng RD; Chen JN; Zhuang QY; Lu YH; Chen J; Chen BF
    Int J Med Sci; 2013; 10(5):641-6. PubMed ID: 23569427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
    Wen QP; Qian H; Ba S; Lu MJ; Silang LDJ; Shi L
    Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):304-308. PubMed ID: 35462487
    [No Abstract]   [Full Text] [Related]  

  • 10. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
    Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
    Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
    J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
    Mi YQ; Liu YG; Xu L; Fan JG; Zhang H; Ping L; Shi RF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):817-20. PubMed ID: 19958639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection.
    Poortahmasebi V; Alavian SM; Keyvani H; Norouzi M; Mahmoodi M; Jazayeri SM
    Asian Pac J Cancer Prev; 2014; 15(9):3879-84. PubMed ID: 24935567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
    Peng D; Han Y; Ding H; Wei L
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis.
    Zheng RD; Xu CR; Jiang L; Dou AX; Zhou K; Lu LG
    Int J Med Sci; 2010 Aug; 7(5):272-7. PubMed ID: 20714438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients.
    Chen X; Zhou J; Wu L; Zhu X; Deng H
    Diabetes Metab Syndr Obes; 2022; 15():673-683. PubMed ID: 35256849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection.
    Sefa Sayar M; Bulut D; Acar A
    Arab J Gastroenterol; 2023 Feb; 24(1):11-15. PubMed ID: 35688683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.
    Yilmaz B; Koklu S; Buyukbayram H; Yalçin K; Korkmaz U; Posul E; Can G; Kurt M
    Afr Health Sci; 2015 Sep; 15(3):714-8. PubMed ID: 26957957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.